Incidence of HIV drug resistance in the context of PrEP use

Indication for HIV-1 PrEP involves the use of antiretroviral medication by HIV-negative persons to reduce the risk of acquiring sexually transmitted HIV infection. Used in combination with other prevention strategies such as safer sex practices, it is an important tool in addressing the global HIV epidemic in adults. PrEP was approved by the European Medicines Agency (EMA) in 2016 and expanded to include high-risk adolescents in December 2017. The aim of the research in this PhD thesis was to address outstanding questions in the field of HIV drug resistance. Clinical studies demonstrated that PrEP efficacy was highly correlated with medication adherence and in combination with safer sex practices. The development of HIV drug resistance compromises the effectiveness of antiretroviral medications for both treatment and prophylaxis